Specific RNA-guided cell depletion

Akribion Therapeutics is developing a unique, RNA-guided, nuclease enzyme-based technology for programmable cell depletion using its G-dase® E payload.
Initially targeting HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC), we are developing and exploring applications in precision oncology and beyond.

Our Technology Advantage

Specific and precise

Up to single nucleotide specificity in differentiation of unwanted vs. healthy cells

Flexible target selection

To choose a new target, only a short gRNA needs to be exchanged

Broad application potential

Potentially gamechanging therapeutic applications in many disease areas

Want to contact us?

Feel free to reach out!

Fill out this field
Please enter a valid email address.
Topic
Select an option
Fill out this field
Newsletter Signup
Select an option